.Attribute Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of people along with HER2+ innovative bosom cancer cells and active or dependable brain metastases presented constant intracranial activity as well as systemic efficiency of T-DXd.